Cardiac imaging for risk stratification in asymptomatic diabetes Scholte, A.J.H.A.
15
0
0
Hele tekst
(2) Chapter. 3.
(3)
(4) artery disease by stress SPECT myocardial
(5) . with type 2 diabetes mellitus
(6)
(7)
(8)
(9)
(10)
(11) ! ""#
(12) . $% &'
(13) . J Nucl Cardiol 2008;15:503-509.
(14) Chapter 3. Abstract Background
(15)
(16) ( (
(17) )#
(18) *
(19) #
(20)
(21)
(22) *
(23) *
(24)
(25) +,- *!( !)()
(26) . *(
(27) /
(28)
(29) !
(30). *
(31)
(32) (
(33) ! !(
(34) ! (*+",'-!* (
(35) ! *
(36) * ! +,,- ! )
(37) !(
(38) ! (+ ,'- * (*0 Methods 1
(39)
(40) *!( !)()
(41) +
(42) 45 6/*
(43) -. *(
(44) /
(45)
(46) !
(47).
(48) !
(49) ,.
(50)
(51) ( (
(52) )#
(53) *
(54)
(55) ! ()
(56)
(57)
(58) 0. ()
(59)
(60) .
(61)
(62)
(63)
(64)
(65) )! 77!
(66) !",'!aging, CAC scoring and 64-slice MSCT coronary angiography. Results '.
(67) *
(68)
(69) ()
(70) +/4>- !
(71) ",'!
(72) .
(73) !*
(74) ! .
(75)
(76) ?5()
(77) +?5>- ( )#
(78) ,, +@B pa)
(79) D@B>E. F ,,GH5@- 65()
(80) +65>- ! ,' * (*+/H()
(81) D/H>E. F IJ5>
(82) -0 166()
(83) . ! ",' HH ( )#
(84) ,,
(85) +@5()
(86) D@4>EGH5@- JH .
(87) , ,' (*+@?()
(88) D/@>EIJ5>
(89) -01/4 pa)
(90) . ! ",' @?()
(91) ( )#
(92) ,,
(93) +B()
(94) D4J>E GH5@- @?()
(95) , ,' (*+B()
(96) D4J>EIJ5>
(97) -0 1#
(98) . @6()
(99) +@6>- G/F * ! )
(100)
(101) J pa)
(102) #
(103)
(104)
(105) F * ! 0 Conclusion K *!( !)()
(106) . *(
(107) /
(108)
(109) !
(110). L
(111)
(112) ! )
(113) # N
(114) L
(115)
(116) (
(117)
(118) *
(119)
(120) 0 !
(121) #
(122)
(123) *
(124)
(125) +,, ,'-
(126) !
(127)
(128) O
(129) * )
(130) #
(131)
(132) +
(133) ",'-0 .
(134) #
(135) . *F !
(136) ) ,.
(137)
(138)
(139) #
(140)
(141) O
(142)
(143) FP *
(144) ! *
(145)
(146)
(147) (
(148) * !
(149) 0'
(150)
(151) )#
(152) ( )#
(153)
(154) ! *
(155)
(156)
(157)
(158)
(159) !
(160) * low-up of this cohort.. 32.
(161)
(162)
(163) .
(164)
(165) !
(166).
(167) !
(168) . .
(169)
(170)
(171) (
(172) ! (
(173) #
(174)
(175) )ues to increase.2, 16, # !( )
(176)
(177) ! !!
(178) ! * ! *()
(179) . *(
(180) /
(181)
(182) !
(183). 07 Moreover, life expectancy F *L
(184)
(185) *
(186) (
(187)
(188)
(189)
(190)
(191) #
(192)
(193) ()
(194) with diabetes mellitus.57" *
(195) )F) ()
(196) .
(197)
(198) *
(199) *
(200)
(201) +,-
(202)
(203) )
(204) *)) (( (
(205)
(206) !
(207) .!*L
(208) # *
(209) .
(210) ( !
(211) 0 .
(212) #
(213)
(214)
(215)
(216) ) ,()
(217) .
(218)
(219)
(220) !.
(221)
(222)
(223)
(224) , P
(225) . *!( !0 K
(226) K *
(227) #
(228) . (
(229) #
(230)
(231)
(232) !*
(233) ! *
(234) (
(235) ! !(
(236) ! (*+",'-.//>0'
(237)
(238)
(239)
(240) !* (
(241) ! )
(242) +@?>- .
(243).
(244) !
(245)
(246) ! +",V-
(247)
(248)
(249) !
(250) P#
(251) ) +?>-036 Anand et al
(252)
(253)
(254) )*
(255)
(256)
(257) *
(258) ",'!
(259)
(260)
(261) * *
(262) * !+,,- F
(263) 043 In recent years, direct noninvasive # N) ,
(264) !
(265)
(266)
(267) . ! )
(268) !(
(269) ! (+ ,'- * (*0'
(270) O
(271) . .
(272) # )
(273)
(274)
(275)
(276) !
(277) F
(278) ( O
(279) ) F) 058, 59
(280) (
(281)
(282) )!
(283)
(284) .
(285)
(286)
(287)
(288) ##
(289) )
(290) O
(291) !
(292) L
(293) )#
(294)
(295)
(296)
(297) ) . *!(
(298) ,*!( !)()
(299) . *(
(300) /
(301)
(302) !
(303). 0 '
(304)
(305)
(306) #) *.
(307)
(308)
(309) #
(310) ( (
(311) )#
(312) * *!( !)()
(313) . *(
(314) /
(315)
(316)
(317) !()#
(318) (
(319) #
(320)
(321)
(322) #
(323)
(324) *
(325)
(326) *
(327) ",' ,, ,' * (*
(328) )
(329)
(330) ) (0. Methods ,
(331) )#
(332) *!( !)()
(333) . *(
(334) /
(335)
(336) !
(337). .
(338)
(339)
(340)
(341)
(342) ()
(343)
(344)
(345) ! */55J) */55?0K
(346)
(347) Z+@- *(
(348) /
(349)
(350) !
(351). [+/-
(352) O#
(353) *!( ![+4- !
(354) )",V0"%
(355) .
(356)
(357) Z+@- . (
(358)
(359) ,[+/- * *
(360) # N) [+4-
(361) !
(362) . ) !
(363) ) [+H-#
(364) 33.
(365) Chapter 3. (#
(366) * ![+J- )
(367)
(368)
(369) !
(370) +.
(371) * \ !
(372) F )
(373) ]?5! \!\@064!2-0*!( !) .
(374)
(375) !
(376)
(377) O
(378) )
(379) ^
(380)
(381) 015'
(382) &!!
(383)
(384) .
(385)
(386) .
(387) !
(388)
(389) @5 *
(390) for coronary heart disease.60.
(391) "
(392) !
(393)
(394)
(395) )! 77!
(396) !+99m'
(397) ![45!,-",'!* (
(398) !.(
(399) !
(400) / *
(401)
(402) ( 0. ()
(403) .
(404)
(405)
(406) !L
(407)
(408) ( !/H
(409)
(410)
(411) )0
(412) .(
(413) !
(414) * #
(415)
(416)
(417) +@H5 μg/kg/minute ? !
(418) - . !
(419) * (
(420) %
(421)
(422) 0
(423)
(424) (
(425)
(426) @/
(427) ",V.
(428)
(429)
(430)
(431)
(432) #
(433) *!
(434)
(435) #
(436) *0K
(437) !",V
(438) .
(439)
(440)
(441) F
(442)
(443)
(444) @ !!j . ('
(445) !
(446)
(447) (
(448) . !
(449)
(450)
(451)
(452) 0",'! !!
(453)
(454) @/5!
(455) P
(456) (!
(457) )
(458) ) (
(459)
(460) ",'!!!
(461) +V,7455\ V ' , ( ) ' * (-0K!
(462) O) .(
(463) !
(464)
(465) .
(466) !
(467)
(468) * q
(469) , *+q,-
(470)
(471) @B5z ?H(
(472) ) /5
(473) \(
(474) ) 061, 62q {
(475) )
(476) ) .((
(477) 0 1
(478)
(479) %(
(480)
(481)
(482)
(483) #
(484) +&' -
(485)
(486) ,, MSCT angiography, interpreted reconstructed stress-rest short- and long-axis slices by visu *0K!
(487) .
(488)
(489)
(490) N
(491)
(492)
(493) ! ! 0
(494) !
(495)
(496) reversibility and stress defect severity were assessed using 17-segment colour-coded polar !( . !
(497)
(498)
(499)
(500) F
(501) 0 |
(502) P #
(503) (
(504) ! )
(505) .
(506)
(507)
(508) N
(509)
(510) O)F) !. +5 J>
(511)
(512) P#
(513)
(514) - !
(515)
(516) +IJ ]@5>-
(517) +I@5>- (
(518) # *
(519)
(520) 036K
(521) !",V
(522)
(523)
(524)
(525) *(
(526) F , .
(527)
(528)
(529) (
(530)
(531) !
(532) ",'
(533) 063. ! ,'.(
(534) !
(535) ?H
(536) ' ! )
(537) O *
(538) !+'
(539) *
(540) ! ' * (-0& * !. .
(541) ( (
(542) )#
(543)
(544) . .
(545) *?H
(546) ,' (*(
(547) !
(548)
(549)
(550) ()
(551) ! ) J!|\34.
(552)
(553)
(554) . cording to the protocols as described previously.64, 65 If the heart rate was greater than
(555) O ?J
(556) \!
(557) ) E
(558) +!
(559) (. J5 @55!
(560)
(561) @
(562)
(563)
(564) %!) -.
(565)
(566) ( #
(567)
(568)
(569) 0%
(570) .
(571)
(572)
(573)
(574)
(575) !
(576) . ) +
(577) / K!
(578) *!
(579) }- ( (
(580)
(581) O
(582)
(583) # ) 0. Coronary artery calcium score '
(584) ,,.
(585)
(586) * .
(587) %(
(588)
(589)
(590)
(591) #
(592) + -
(593)
(594) P.
(595) +
(596) / K!
(597) -0'
(598) ,,.
(599) )F
(600)
(601)
(602)
(603)
(604) ) *
(605) *
(606) %
(607)
(608)
(609)
(610) @45 F
(611) +}-0 #
(612) .
(613) .
(614)
(615)
(616) *
(617) * (
(618) ()
(619) 0
(620) N) .((
(621) Z
(622) @5 !! [@@ @55 ! [@5@ H55 !
(623)
(624) [H5@ @555
(625) #
(626)
(627) [
(628)
(629) @ 555
(630) %
(631) #
(632) 0. The MSCT coronary angiograms were evaluated by the same two experienced observers + - . .
(633)
(634) .
(635)
(636)
(637) ",'!0, *
(638)
(639) .
(640)
(641) #
(642) @6
(643) !
(644)
(645) ! F
(646) !
(647)
(648) ) F)
(649)
(650) !
(651)
(652)
(653) #
(654) *# (
(655) ) 066
(656) O
(657) * interpretable segments were evaluated for the presence of luminal stenoses, both by .
(658) % !
(659) *(
(660) )#
(661) ! )(
(662) ) 0 F * ) .
(663) F
(664)
(665) (
(666)
(667)
(668)
(669) @
(670)
(671)
(672) J5> ! .
(673)
(674) #. *0q )#
(675) ,.
(676) F
(677) *
(678) (
(679)
(680)
(681)
(682)
(683)
(684) %
(685)
(686) J5> ! .0q !
(687)
(688) .
(689)
(690)
(691) F
(692)
(693)
(694)
(695) *
(696) #
(697)
(698) *
(699)
(700) 0. ,
(701)
(702)
(703)
(704) )
(705)
(706) %(
(707)
(708) !
(709) (
(710)
(711)
(712) 0, ) #
(713)
(714)
(715) %(
(716)
(717) !
(718) +~
(719) #) -0 )) *
(720) .
(721)
(722) (
(723) !
(724) P.
(725) +#
(726) @/05 K0 , K. }- P.
(727) +*
(728) !
(729)
(730)
(731) ?0@/ K)
(732) K0 ,* q , -0P]505J.
(733)
(734) )). *F 0 35.
(735) Chapter 3. Results K @6?
(736) )#
(737) ()
(738) .
(739)
(740)
(741)
(742)
(743) 0% *
(744) +47>-()
(745) .
(746)
(747)
(748)
(749)
(750) *0'.
(751) * F#
(752) +@H>-()
(753) !
(754) )",V H ()
(755) . F. ) 0q
(756)
(757)
(758) +@@>-()
(759) .
(760)
(761) ) !
(762) )
(763) (*!( !0
(764) #
(765) +H>-()
(766) )
(767)
(768)
(769) !
(770) 0"
(771)
(772) +@5>-()
(773) O
(774) )
(775) ^
(776)
(777) . ( )#
(778) 0 ,
(779) O
(780) * @56+?@>-()
(781) .
(782)
(783)
(784)
(785)
(786) *0& ()
(787)
(788)
(789) ()(
(790) [
(791) ()
(792) .
(793)
(794) %
(795)
(796)
(797)
(798) (
(799)
(800) ",'!
(801) / ()
(802)
(803)
(804)
(805) (
(806)
(807) ,'0 '
(808) F * ( ( )
(809) @55()
(810) +?J!
(811) [
(812) J4~@5*
(813) -0'
(814) ()
(815)
(816) )
(817) shown in Table 1. '
(818) !
(819) )
(820)
(821) !
(822). .70H~605*
(823) 0
(824) ()
(825) .
(826)
(827) )
(828) )
(829) (*+?@>-0 ).
(830)
(831)
(832) *JH>
(833) ()
(834) 0' *
(835) #
(836) ()
(837) !( )
(838)
(839) !
(840). (
(841) (
(842) #
(843)
(844) +@H- (
(845) (
(846)
(847) ( *
(848) ) ( *0.
(849) '.
(850) *()
(851) +/5>-
(852) (
(853) ! )
(854) +&
(855) @-0"
(856)
(857)
(858)
(859) (
(860) ! )
(861) .
(862)
(863)
(864) #
(865)
(866)
(867)
(868) 0
(869) (
(870) ! )
(871) .
(872)
(873)
(874) )#
(875) * !. [ * 4 ()
(876) !
(877)
(878) N
(879) (
(880)
(881)
(882) 0 K
(883) ! ",V
(884)
(885)
(886)
(887) ?()
(888) 0'
(889)
(890)
(891)
(892) ()
(893)
(894) (
(895) ! )
(896) Z . .
(897)
(898) !.
(899) .!
(900)
(901) N
(902) 0 '
(903)
(904)
(905)
(906) ()
(907) ! (
(908) 0K /4()
(909) +/4>- !
(910) (
(911)
(912) +&
(913) @-0. " q ,,.(
(914)
(915) H5()
(916) +H5>-0% *()
(917) +?5>-
(918) #
(919)
(920) ,,0$*
(921) ! !.!! J+J>-()
(922) ! /@+/@>- ()
(923) !
(924)
(925) @?+@?>-()
(926)
(927) #
(928)
(929) @B()
(930) +@B>-01@B()
(931) .
(932)
(933)
(934) H5@ 6()
(935)
(936)
(937)
(938) @ 555+&
(939) @-0 36.
(940)
(941)
(942) . Table 1.,
(943) ) @55*!( !)()
(944) . *(
(945) /
(946)
(947) 0 V
(948)
(949) + \&
(950) +*
(951)
(952)
(953)
(954)
(955)
(956) ) +*
(957) )!
(958)
(959)
(960) +*HbA1C+>Treatment
(961) * Oral Insulin and oral agent Insulin ^
(962) ) ( * Peripheral vascular disease* $ *!
(963) %+ \!2 !
(964)
(965)
(966) +!Microalbuminuria Hypertension Hypercholesterolemia &! * * , Smoking Past Current
(967) ) Aspirin ," \^$ ). 65/35 53 ± 10 9.4 ± 7.0 44 ± 12.0 7.3 ± 1.6 5+5>?@+?@>@?+@?>/4+/4>@/+@/>@H+@H>29 ± 5.0 102 ± 13.0 HJ+HJ>J@+J@>J4+J4>J@+J@>/H+/H>@/+@/>/@+/@>4J+4J>-\/5+/5>JH+JH>-.
(968)
(969) (
(970)
(971)
(972) !
(973) +) >- !
(974) ~
(975) #) 0 ,"
(976) #
(977) )
(978) N*!
(979) [ ^$
(980)
(981)
(982) (
(983) [ 1c, haemoglobin A1c[ , *
(984) *
(985)
(986) [* *
(987) [ ![!2 O
(988) !
(989)
(990) 0 * Peripheral vascular disease was determined based on clinical history ( )#
(991) ! * *.
(992) F
(993) *
(994) ,(
(995)
(996)
(997)
(998)
(999) J5*
(1000) . ! ,' * (* . ! 45 ()
(1001) +45>-0 '
(1002)
(1003) ! 65 ()
(1004) +65>- .
(1005) ! .
(1006) !
(1007) *
(1008)
(1009) +&
(1010) @-0 & * % )#
(1011)
(1012)
(1013) @@
(1014) #
(1015)
(1016) # #
(1017) !
(1018) +/H>- @? . #
(1019)
(1020) # #
(1021) !
(1022) +4J>- @7
(1023)
(1024) #
(1025)
(1026) # #
(1027) !
(1028) +H@>-0 '.
(1029) * ()
(1030) +/H>- F ! .
(1031)
(1032) J5>
(1033)
(1034) #
(1035)
(1036) # #
(1037) !
(1038) B+44>- . #
(1039)
(1040) # #
(1041) !
(1042) @?+?6>- .
(1043)
(1044) #
(1045)
(1046) # #
(1047) !
(1048) 01
(1049) ()
(1050)
(1051)
(1052) J5>
(1053) P! * artery stenosis. 37.
(1054) Chapter 3. # &' ) +>- )F
(1055)
(1056) (
(1057) ! !(
(1058) ! (* +",'- *
(1059) * ! +,,- ! )
(1060) !(
(1061) ! (* + ,'- (* @55 *!( !) ()
(1062) . *(
(1063) /
(1064)
(1065) 0 SPECT S C SPECT 3% 3% 3% 3%. Normal N Normal l. 17% 17%. Small defects Small defects Moderate M d Moderate defects ddefects f 1 *
(1066) !",V Only y ischemic ECG 77% 77%. MSCT Angiography A i h MSCT A . CAC Score CAC Score 7% 7% %. 24% 24% 24%. 11% 11%. 30% 30% 30%. 40% 40% 0 1-10 11-100 101 101400 101-400 >401-1000 401 401-1000 1000 >G@555 1000 0. 16% 16%. Normal N Normal l ]J5>
(1067) < 50% stenosis G50%stenosis. 1-10 1 10 11 100 11-100. 21% 21%. 5% 5%. 46% 46% 46%. 50 % stenosis. # $ % '
(1068)
(1069) ) (
(1070) .
(1071)
(1072) &!!
(1073) ! F
(1074) ",' ,, ,' * (* .'
(1075) /0q
(1076) )
(1077) .
(1078)
(1079)
(1080) ! !F .
(1081) #
(1082) 0 " '
(1083)
(1084) ) (
(1085) .
(1086)
(1087) ,,
(1088) ",'! .&
(1089) /01 66()
(1090) . ! ",'! 44+H4>- ,, ,,.(
(1091)
(1092) HH +J6>-0'
(1093) !
(1094) ,,
(1095)
(1096)
(1097) HH()
(1098) ./6B~47H0'
(1099) ,,
(1100) .!! H()
(1101) +7>- ! @J()
(1102) +44>- !
(1103)
(1104) @J()
(1105) +44>-0'
(1106) ()
(1107) +@4>-. ! ",' ,,
(1108)
(1109)
(1110) H5@ ..
(1111) #
(1112)
(1113) B()
(1114)
(1115) %
(1116) #
(1117) +
(1118)
(1119) @ 555-/()
(1120) 0 1/4()
(1121) . ! ",'! 6()
(1122) +45>-
(1123) #
(1124)
(1125) ,,0 38.
(1126)
(1127)
(1128) . Table 2.^
(1129) )
(1130) .
(1131)
(1132) ! ",' ,,
(1133)
(1134)
(1135)
(1136) O H5@} ,' * (* )
(1137)
(1138)
(1139)
(1140) O J5> &!!
(1141) @55*!( !)()
(1142) . *(
(1143) /
(1144)
(1145) 0. ! ",' ,,
(1146) IH5@} ,' * (*IJ5>
(1147) . Low risk n=39. Intermediate risk n=42. ( $ n=19. @/+4@>J+@4>H+@5>-. ?+@H>B+@7>@H+44>-. J+/?>J+/?>?+4/>-. } [,,
(1148) *
(1149) * !
(1150) [ ,' ! )
(1151) !(
(1152) ! (*[",'
(1153) ( emission computed tomography.. # )' , *
(1154) *, !+,,-
(1155) !
(1156) ()
(1157) . ! !
(1158) (
(1159) ! !(
(1160) ! (*+",'-!0 100. SPECT q ! 66 ! /4. * %
(1161) . 80. 60. 40. 20. 0 q
(1162) (40). ]@5. @@ @55. (5). (21). @5@ H55 (16). G401 (18). =n. CAC Score. K
(1163) @?
GERELATEERDE DOCUMENTEN
Detection of amyloid plaques in mouse models of Alzheimer’s disease by magnetic resonance imaging.. Apostolova
Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden.. Note: To cite this publication please use the final
Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden.. Note: To cite this publication please use the final
Niet-invasieve coronairangiografie met multislice computer tomografie heeft een toegevoegde diagnostische waarde ten opzichte van de coronaire calciumscore in
Since expression of Serpins may facilitate the immune escape of HLA positive tumors, we next analysed the effect of Serpin expression on survival in cases with normal/partial
Peripheral blood cells were stained with HLA-A2.1 tetramers containing the tyrosinase368–376 peptide followed by staining with a panel of lineage antibodies, as described in
Blades and blade fragments seem to have been especially used for longitudinal motions, mainly on plant material (7/12). Flake and flake fragments are used in different motions on
This shape also occurs in the combination artefacts (see below). The shape is the result of intensive use in a repetitive abrasive motion, carried out from different angles. In
